Overview

Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease

Status:
Unknown status
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
Objectives: To describe the safety and efficacy of intravitreal flucinolone acetonide implants in the management of patients having refractory ocular Behcet's disease Hypothesis: A descriptive observational study Study design: A 1-year, multi-center (including four Korean medical centers) observational study
Phase:
Phase 4
Details
Lead Sponsor:
Asan Medical Center
Collaborators:
Kyunghee University Medical Center
Samsung Medical Center
Seoul National University Hospital
Treatments:
Fluocinolone Acetonide